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Abstract
Background: Neurogranin (Ng) is a small 7.6 kDa postsynaptic protein that has been detected at elevated concentrations
in cerebrospinal fluid (CSF) of patients with Alzheimer’s disease (AD), both as a full-length molecule and as fragments from
its C-terminal half. Ng is involved in postsynaptic calcium (Ca) signal transduction and memory formation via binding to
calmodulin in a Ca-dependent manner. The mechanism of Ng secretion from neurons to CSF is currently unknown, but
enzymatic cleavage of Ng may be of relevance. Therefore, the aim of the study was to identify the enzymes responsible
for the cleavage of Ng, yielding the Ng fragment pattern of C-terminal fragments detectable and increased in CSF of AD
patients.
Methods: Fluorigenic quenched FRET probes containing sequences of Ng were utilized to identify Ng cleaving activities
among enzymes known to have increased activity in AD and in chromatographically fractionated mouse brain extracts.
Results: Human Calpain-1 and prolyl endopeptidase were identified as the candidate enzymes involved in the formation
of endogenous Ng peptides present in CSF, cleaving mainly in the central region of Ng, and between amino acids 75_76
in the Ng sequence, respectively. The cleavage by Calpain-1 affects the IQ domain of Ng, which may deactivate or change
the function of Ng in Ca2+/calmodulin -dependent signaling for synaptic plasticity. While shorter Ng fragments
were readily cleaved in vitro by prolyl endopeptidase, the efficiency of cleavage on larger Ng fragments was
much lower.
Conclusions: Calpain-1 and prolyl endopeptidase cleave Ng in the IQ domain and near the C-terminus, respectively,
yielding specific fragments of Ng in CSF. These fragments may give clues to the roles of increased activities of these
enzymes in the pathophysiology of AD, and provide possible targets for pharmacologic intervention.
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Background
Synapses are the key physiological units in the central
nervous system (CNS) and are central for neuronal sig-
nal transmission as well as memory and cognitive func-
tions. Disturbances in memory formation, as observed in
Alzheimer’s disease (AD), are associated with synaptic
degeneration and loss [1]. Indeed, a decreased density of
synapses in mid-frontal and inferior parietal sections of
the brain has been found to show tighter correlation to
cognitive impairment in AD than amyloid plaques and
tangles [2]. The measurement of synaptic proteins in
cerebrospinal fluid (CSF), released during synaptic degen-
eration, is therefore a possible route to monitor synaptic
pathophysiology in man [3]. Further, the mechanism of re-
lease of synaptic proteins may involve one of several con-
ventional or non-conventional active mechanisms [4], or
merely reflect passive secretion occurring during cell
death which may be more relevant at later stages of AD.
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Recent research showed that particular synaptic pro-
teins, such as neurogranin (Ng) can be detected in CSF
at increased levels already at early stages of AD, both as
apparently full length protein [5] and as proteolytic en-
dogenous fragments [6].
Increased concentrations of Ng in CSF correlate with
future rate of cognitive deterioration and other measures
of disease progression [6, 7], and the increase appears to
be specific to AD and is not seen in many other neuro-
degenerative diseases [8, 9].
Ng is a 7.6 kDa neuronal protein [10–13] localized pri-
marily in the cell body and dendrites. By using immuno-
gold electron microscopy, Ng has been detected
preferentially near the plasma membrane of dendritic
spines [14]. Ng has two known mutually exclusive intra-
cellular binding partners, calmodulin (CaM) [15] and
phosphatidic acid (PA) [16] . Essential for this binding is
the IQ domain of Ng, so-called because of the presence
of the amino acids isoleucine (I) and glutamine (Q). The
IQ domain is well conserved among a number of
CaM-binding neuronal proteins, such as
growth-associated protein 43 (GAP-43) and PEP-19 (also
called purkinje cell protein 4, pcp4) [17]. Moreover, the
main function for Ng appears to be to modulate CaM’s
signal transduction pathways of CaM dependent en-
zymes to enhance synaptic plasticity [12] in long term
potentiation (LTP).
Molecular characterization of Ng in the CSF by
immuno-enrichment using a specific Ng antibody and
subsequent immunoblotting suggested that Ng is present
as a protein with an apparent molecular weight of ~
12 kDa [5]. However, detection by mass spectrometry
showed various endogenous fragments representing
approximately the C-terminal half, all but one lacking
the IQ domain [6]. Fragments representing the
N-terminal half were not identified in that study. The
C-terminal fragments are not generated by in vitro deg-
radation of the protein in the CSF [18] and may instead
be released from degenerating synapses in the CNS dur-
ing the progression of the disease. These C-terminal Ng
fragments were frequently truncated at Ng75, thus miss-
ing the last three amino acids (-SGD) at the C-terminus.
Altogether, it appears that in CSF, Ng is present both as
a full-length molecule and as fragments where major
cleavages seem to be in the middle region and at/or near
position 75. The enzyme(s) responsible for the gener-
ation of those fragments of Ng are unknown.
The important role of Ng in synaptic function and
cognition was highlighted from a gene deletion mouse
model that illustrated the deficits of these animals in
learning and memory. Ng deficient mice also exhibited
several behavioral abnormalities, most severe in the Ng
knock-out mice (−/−), and less severe in hemizygote
mice (−/+) with intermediate expression of Ng [19]. On
the other hand, overexpression of Ng seems to be able
to counteract negative effects of amyloid β (Aβ) oligo-
mers on synaptic transmission, as determined by meas-
uring evoked excitatory postsynaptic currents (EPSC) on
Ng overexpressing neurons in rat hippocampal slices
[20]. Thus, it appears that maintenance of a normal level
of this protein in neurons is essential for proper cogni-
tion and a reduction of Ng upon aging and degenerative
diseases may result in negative cognitive symptoms.
Enzymatic cleavage of Ng may be the first step to-
wards a diminished function of Ng, or its loss to the
brain interstitial fluid and, consequently, CSF. The aim
of this study was to identify enzymes that can produce
Ng fragments having the same or similar N- and
C-termini as seen on some of the most prominent
C-terminal peptides identified in the CSF and brain of
patients with AD.
Methods
Animals
Female C57BL/6 J mice from Charles River Laboratories
(Sulzfeld, Germany) were used in this study. The mice
were kept on a 12-h light cycle with food and water pro-
vided ad libitum. The room temperature was 19–21 °C
with 40–70% relative humidity. All experiments were
approved by the Swedish Animal Welfare Agency.
Preparation of mouse brain extract
The brains from ten eight-week-old female mice were
quickly removed after sacrifice, put in liquid nitrogen,
and stored at − 80 °C. While still frozen, the cerebelli
were pinched off with a spatula. Homogenization of the
brain tissue (3.48 g) was performed with 3 to 4 bursts of
about 30 s with an Ultra-Turrax homogenizer (IKA T10
basic) with disposable tips (S10D-7G-KS-65) on ice. The
homogenization buffer (50 mM Tris-HCl, pH 7.8, 1 mM
DTT; ice cold) was used in about six times excess
(21 mL) over the total wet brain weights.
Homogenization was finished within 10 min. The raw
extract was then diluted with ice-cold homogenization
buffer to 35 mL and centrifuged 30 min at + 4 °C at
40,000 x g (SW28 rotor on Beckman ultracentrifuge).
Further, the supernatant was centrifuged again at
100,000 x g, + 4 °C for one hour, aliquoted and stored at
− 80 °C (protein concentration by BioRad DC protein
test: 3.3 mg/mL; calibrator: BSA).
Antibodies
The C-terminal region specific neurogranin antibodies
NG36 and NG22 were prepared in-house using human
peptides Ng63–77 and Ng63-76, respectively, as immu-
nogens, and the neurogranin antibody H-6 was pur-
chased from Santa Cruz Biotechnologies (#sc-514922).
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Gel electrophoresis and western-blotting
SDS PAGE gels (12% BisTris) were run in MES buffer
and equilibrated afterwards for 25 min in 1× transfer
buffer containing 20% MeOH (all gels and buffers from
BioRad or Life Technologies). The proteins were trans-
ferred to a nitrocellulose membrane (Protran 0.2 μm;
Amersham #10600001) in a semi-dry blot apparatus at
0.8 mA/cm2 at room temperature for 60 min, followed
by drying of the membrane overnight. Further fixing of
the transferred proteins was done by incubating the
membrane in 0.4% formaldehyde (1:40 dilution of
Thermo Sci # 28906) in PBS for 30 min at room
temperature under light shaking. After three washes
(10 min) with PBST (PBS with 0.05% Tween 20), the
membrane was blocked with 5% dry milk powder
(BioRad #170–6404) in PBST. Further processing and
detection of signals by ECL (GE Healthcare, #RPN2235)
was done according to standard procedures.
Detection of cleavage of quenched FRET probes by
calpain-1
The quenched FRET peptides ((2-Abz)-AKIQASFR
GHK(Dnp), (2-Abz)-GHMARKKIKSGERK(Dnp), and
(2-Abz)-GAGGGPSGDK(Dnp) (Caslo, Denmark) con-
taining sequences Ng31–40, Ng39–51, and Ng70–78, re-
spectively, were each digested with calpain-1 at room
temperature. The assay mix (80 μL per well in a
384-well plate; AlphaPlate-384, PerkinElmer) consisted
of 12.5 μM quenched peptide in 25 mM Tris-HCl,
pH 7.5, 1 mM CaCl2 and 6 units of calpain-1 (hu eryth-
rocytes calpain-1; Millipore 208713). Controls contained
assay buffer and quenched peptide but no enzyme. The
developing fluorescence was measured during 30 min on
a Molecular Devices Spectramax Gemini reader (excita-
tion 320 nm, emission 420 nm).
Preparation of untagged recombinant Ng via 6xHis-
SUMO-Ng fusion protein
Human Ng1–78 cDNA was PCR-amplified using the ORF
clone RC201209 from Origene as template and primers
5’ATGGACTGCTGCACCGAGAAC 3′ and 5´ CTAG
TCTCCGCTGGGGCCGCCGCC 3′. Cloning into the
pET_SUMO vector and protein expression in E. coli BL21
(DE3) were performed according instructions of the
“Champion pET SUMO expression system” (Invitrogen
#K30001). The expressed 6xHis-SUMO-Ng fusion protein
in the E. coli cell pellet was extracted with 5 mL/mg 1×
Bind/Wash buffer (50 mM sodium-phosphate, pH 8.0,
300 mM NaCl, 0.01% Tween 20) plus 0.5% NP40 and in-
cubated with rotation at room temperature for 30 min,
after which the lysate was centrifuged at 17000 x g for
20 min at + 4 °C and the supernatant was collected. Fur-
ther, the fusion protein was isolated using the “Dynabeads
His-tag Isolation & Pulldown” kit (Life Technologies #
10104D). The fusion protein (approximately 400 μg from
1 L initial culture) was concentrated and the buffer ex-
changed to 20 mM Tris-HCl, pH 8.0, 150 mM NaCl,
1 mM DTT on Amicon Ultra 4 (Merck Millipore) with
molecular weight cut-off (MWCO) 10 K. Cleavage reac-
tion to remove the 6xHis-SUMO tag was performed ac-
cording to instructions using materials of the pET SUMO
expression system kit. Briefly, a 200 μL digestion mix con-
tained 20 μg fusion protein, 1× SUMO Protease buffer
without salt, and SUMO Protease 10 μL (10 U). Digestion
was carried out at + 30 °C for four hours. Removal of
6xHis-SUMO tag and His-tagged SUMO Protease was
done with the “Dynabeads His-tag Isolation & Pulldown”
kit. Beads were collected and the untagged protein in the
supernatant was concentrated and the buffer was ex-
changed to 20 mM HEPES, 300 mM NaCl, 2 mM TCEP,
pH 7.5 on Amicon Ultra 4, 3 k MWCO (molecular weight
cut-off).
In vitro cleavage of Ng-Myc-DDK fusion protein by
calpain-1
Recombinant Ng-Myc-DDK fusion protein (1.6 μg in
20 μL; Origene Technologies TP301209) was incubated
in the presence of 100 μM CaCl2 with 2 μL calpain-1
dilution in a final volume of 40 μL for 1 h at room
temperature. The calpain-1 dilutions were prepared by
diluting the enzyme stock solution (human erythrocytes
calpain-1; Millipore #208713; 1.68 mg/mL; specific activ-
ity 2069 units/mg) in 25 mM Tris-HCl, pH 7.5, in vari-
ous dilutions (3.3 to 90-fold). Aliquots of half (20 μL) of
the cleavage mixtures were used for SDS/PAGE (redu-
cing conditions) and the remaining halves (20 μL) for
mass spectrometric analysis (described further below).
In vitro cleavage of recombinant Ng1–78 protein by
calpain-1
Approximately 1.5 μg (7.5 μL) recombinant untagged Ng
were digested in the presence of 100 μM calcium chloride
and 12 mM Tris-HCl, pH 7.5 with 1 μL calpain-1 dilution
in a total volume of 20 μL. Calpain enzyme was the same
as used for the cleavage of Ng-Myc-DDK fusion proteins,
at 10-, 30- and 90-fold dilutions in 25 mM Tris-HCl,
pH 7.5. The digestions were carried out for 90 min at
room temperature. Most of each sample (15 μL) was used
for SDS-PAGE (12%) followed by Coomassie and silver
staining, and 2.5 μL for each of the immunoblots (NG36
and H-6 antibodies).
Mass spectrometric analysis of calpain-1 cleavage
products
Twenty μL of the calpain-1 digests of Ng-Myc-DDK
fusion protein were acidified with 1.6 μL 10% trifluoroa-
cetic acid and frozen before the analysis. Nanoflow li-
quid chromatography (LC) coupled to electrospray
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ionization (ESI) high resolution hybrid quadrupole–orbi-
trap mass spectrometry (MS) was performed with a
Dionex 3000 system and a Q Exactive (both Thermo
Fisher Scientific, Inc.). The centrifuged sample solution
was loaded onto an Acclaim PepMap C18 trap col-
umn (length 20 mm, i.d. 75 μm, particle size 3 μm,
pore size 100 Å, Thermo Fisher Scientific, Inc.) for
desalting and sample cleanup. Sample loading buffer
was 0.05% trifluoroacetic acid/2% acetonitrile/water (v/
v/v). Separation was performed by a reversed-phase Ac-
claim PepMap C18 analytical column (length 150 mm,
i.d. 75 μm, particle size 2 μm, pore size 100 Å, Thermo
Fisher Scientific, Inc.). Separation was performed at a
flow rate of 300 nL/min by applying a 50 min long lin-
ear gradient from 3 to 40% B. Buffer A was 0.1% formic
acid/water (v/v) and buffer B was 0.1% formic acid/84%
acetonitrile/water (v/v/v). The mass spectrometer was
set to operate in data-dependent mode, i.e., acquiring
fragment mass spectra whenever the acquisition soft-
ware detected peptide peaks above threshold intensity.
Spectrum deconvolution and database searches were
performed either using Mascot Distiller 2.6.3 and Mas-
cot Daemon 2.6.0/Mascot search engine 2.6.1 or
PEAKS Studio 8.5 against a custom-made neurogranin
database as well as Uniprot KB human.
Size exclusion chromatography (SEC) of preparations with
Ng C-terminal cleaving activity
An aliquot (500 μL) of sample (raw or partially purified
brain extract) was injected onto a 300 × 10 mm Super-
dex 200 column (GE Healthcare) in a cold room (+ 4 °
C). Separation was performed at 0.4 mL/min and frac-
tions of 0.5 mL were collected. Prior to the separation,
the column had been calibrated using blue dex-
tran (marking void volume), bovine serum albumin
(66 kDa), carbonic anhydrase (29 kDa; from bovine
erythrocytes), cytochrome C (12.4 kDa; from horse
heart) and aprotinin (6.5 kDa; from bovine lung) as size
markers. C-terminal cleaving activity was determined in
the collected fractions using the fluorogenic assay de-
scribed below.
Fluorogenic assay for detecting C-terminal cleavage
activity
The assay utilized the quenched fluorogenic peptide
Ng70–78 ((2-Abz)-GAGGGPSGDK(Dnp)) at 12.5 μM
and 1 mM CaCl2. CaCl2 in the assay buffer should
enable activity of Ca2+-dependent proteases, potentially
present in the samples. In the assay, samples (52 μL; e.g.
ion-exchange or size exclusion chromatography (SEC)
column fractions) were combined with 28 μL of a mix of
220 μL 50 μM quenched peptide and 88 μL 10 mM
CaCl2. Fluorescence increase was recorded in kinetic
mode on a Spectramax Gemini at 320 nm/420 nm (exci-
tation/emission) in wells of a 384-well plate
(PerkinElmer, #FP1342, black) for up to 30 min at room
temperature.
Chromatographic enrichment of enzymatic activity from
mouse brain extract
A Tricorn 10/100 mm column (GE Healthcare) was filled
with Q-Sepharose high performance gel (GE 17–1014-01)
and equilibrated in a cold room (+ 4 °C) in buffer A
(25 mM Tris-HCl pH 7.5, 10% glycerol). Mouse brain ex-
tract (10 mL; 3.3 mg protein/mL) was injected into the
column and separation was performed using a linear gra-
dient of buffer A and B (0–20 min: 0% B; 20–60 min: 0–
50% B; 60–63 min: 50–80% B; 63–68 min: 80% B; 68–
71 min: 80–0% B; 71–91 min: 0% B) at a flow rate of
1 mL/min. Buffer B was buffer A with added NaCl (to
1 M). Fractions of 1 mL were collected and aliquots ana-
lyzed for enzymatic activity.
Active fractions #40–45 from the Q-Sepharose column
were pooled (6 mL) and concentrated on YM-10 ultrafil-
tration membranes (Centricon tubes, 2 mL; #4205, Ami-
con). An aliquot (approximately 2.2 mL) of the active
pool was applied to the device and spun at + 4 °C, 5000
x g for about 80 min in a SM-24 rotor (Sorvall) to yield
a concentrate of about 800 μL. The tube was refilled
with more of the active pool and concentrated again; this
was repeated four more times until about 1 mL of con-
centrate and 5 mL of filtrate were obtained. Total time
of centrifugation was approximately 5.5 h. Prior to an
additional anion-exchange separation on a high resolving
Mono Q column, the concentrate was desalted by SEC
(Superdex 200 column, as described above). Fractions
containing C-terminal cleaving activity on neurogranin
(#23–28) were pooled and stored at + 4 °C prior to the
Mono Q column separation step.
The pool of active fractions from the Superdex 200
column (approx. 2.5 mL) was diluted with the same vol-
ume of 10% glycerol to reduce the salt concentration to
25 mM. In a cold room (+ 4 °C), this sample was applied
onto a pre-equilibrated Mono Q column (5 × 50 mm;
Pharmacia #17–0546-01) and eluted with a linear gradi-
ent of buffer A (25 mM Tris-HCl pH 7.5, 10% glycerol)
and B (=A with 1 M NaCl) at a flow rate of 0.5 mL/min.
Gradient profile: 0–10.5 min: 0% B; 10.5–40.5 min: 0–
40% B; 40.5–45.5 min: 40–80% B; 45.5–50.5 min: 80% B;
50.5–53.5 min: 80–0% B. During loading and before start
of the gradient, ten fractions of 1 mL were collected,
thereafter the fraction size was reduced to 0.5 mL. The
fractions were analyzed for enzymatic activity and stored
at + 4 °C before the next step of analysis (native gel
overlay).
Native gel overlay with fluorogenic substrate
Prior to native gel electrophoresis, 150 μL of the fraction
with peak enzymatic activity from the Mono Q column
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(fraction 38) was further concentrated and desalted in a
0.5 mL 10 K spin filter (Millipore UFC501024) at 14,000
x g, + 4 °C, 30 min. Briefly, the concentrate (50 μL) was
diluted with 150 μL cold 25 mM Tris-HCl, pH 7.5, 10%
glycerol, and concentrated again as before. The dilution
and concentration was repeated once more. Fifteen μL
of the final concentrate was mixed with 15 μL native gel
sample buffer (2×; Novex LC2673) and loaded on a 10%
Tris-Glycine gel (Lifetechnologies EC6075BOX) using
Novex Tris-Glycine native gel running buffer. After elec-
trophoresis (110 V, 2.25 h), the gel was briefly rinsed in
water and incubated in 50 mM Tris-HCl pH 7.5 for
10 min with light shaking. Further, the gel was soaked in
5 μM fluorescence-quenched peptide 5-FAM-GAGG
GPSGDK(QXL520) (Eurogentec) in 50 mM Tris-HCl,
pH 7.5 for 15 min before imaging on a UV bench using
a FITC filter set on the LAS3000 imager (Fujibio). The
UV bench had an additional “Superbright” filter (Vilber
Lourmat) to reduce background of non-UV light. Fluor-
escent bands and non-fluorescent control bands were
cut out from the gel and processed for mass spectromet-
ric analysis.
In vitro cleavage of Ng1–78 and Ng43–78 by human PREP
The cleavage reaction contained 400 ng of Ng peptide,
20 mM NaCl, 25 mM Tris-HCl, pH 7.5, and 1 μL of re-
combinant human PREP (R&D Systems, #4308-SE-010;
0.44 mg/mL) in a total volume of 10 μL. After one and four
hours at 37 °C, samples of 5 μL were taken, diluted on ice
with 5 μL water and directly analyzed by LC-MS/MS.
Mass spectrometric identification of C-terminally cleaving
enzyme
The cut out bands were processed according to a stand-
ard protocol (reduction with DTT, followed by alkylation
of reactive cysteines with iodoacetamide and digestion
with trypsin). LC-MS/MS analysis was performed as de-
scribed above except that an Orbitrap Fusion mass spec-
trometer (Thermo Fisher Scientific, Inc.) was used
instead of a Q Exactive. Peptides were searched using
Mascot search engine 2.5.1 against Swiss-Prot database
(taxonomy: Mus musculus).
Results
Identification of calpain-1 as the enzyme cleaving Ng in
the IQ domain
Most of the Ng peptides identified in human CSF showed
N-terminal endings between amino acid (aa) 41 and 49
and C-terminal endings between aa 75 and 78 (see Fig. 1;
modified from ref. [6]). Hence, fluorescence-quenched
FRET probes encompassing these sequence regions were
utilized to detect relevant endogenous cleaving activity for
Ng in brain tissue, the likely source for the CNS Ng pep-
tides. It has been reported that excitatory overstimulation
of neurons can lead to excitotoxicity involving activation
of calpains via the influx of Ca-ions [21]. Therefore, three
quenched FRET probes were tested for cleavage by human
calpain-1. This enzyme cleaved the quenched Ng39–51
and Ng31–40, but not the C-terminal probe Ng70–78
(Fig. 2).
Calpain cleavage of Ng was further confirmed using
recombinant full-length Ng substrate (Ng-Myc-DDK) in
an in vitro cleavage assay with human calpain-1. As can
be seen in Fig. 3a, lane 4, only one predominant band
was observed, indicating one or more co-migrating
cleavage products of about 8 kDa (apparent MW), which
was also immunoreactive to the C-terminal region spe-
cific NG22 mAb (Fig. 3b).This places the cleavage site
approximately in the same region as contained in the
quenched FRET peptide Ng39–51. Further digestion
with higher concentration of calpain-1 resulted in an
additional weaker band at around 5–6 kDa (Fig. 3a, lane
3; seen also weakly in lane 4). Since the Myc-DDK tag
on the fusion protein may have influenced the cleavage
pattern on the Ng_Myc-DDK fusion protein, Ng was
expressed in the SUMO expression system, which allows
the complete removal of expression vector-derived
amino acids from the expressed Ng. The
SDS-PAGE-separated cleavage mix (Fig. 4a) showed the
conversion of full-length Ng (approx. 12 kDa;
Coomassie-silver stain, lane 1) to a major cleavage prod-
uct of around 5 kDa (lanes 2–4) and a faintly stained
band around 6.5 kDa (lanes 2, 3), thus indicating that
the cleavage by Calpain-1 mainly occurs close to the
center of the molecule. The N-terminal half of Ng is
highly acidic and stains only weakly with
Coomassie-silver stain; the band intensities therefore do
not reflect quantities. The band at 5 kDa represented the
C-terminal half of Ng, as seen by reactivity towards
NG36 (a monoclonal antibody raised against Ng63–75)
(Fig. 4b). This blot also revealed that the 5 kDa band
was composed of at least two bands of similar size (dif-
ference estimated to about 700 Da), which appeared
stable even at the highest calpain-1 concentration used
(Fig. 4b, lane 4). These bands migrated and stained with
Coomassie in about the same manner as synthetic
Ng43–78 (data not shown); in contrast, the N-terminal
half of Ng, as detected by the H-6 monoclonal antibody
(raised against Ng1–50), generated several fragments of
intermediate sizes and was further cleaved at higher
calpain-1 concentrations (no band in lane 4 detected in
Fig. 4c). The strongest intermediate band (around
6.5 kDa) co-migrated with synthetic Ng1–42 (data not
shown). A more precise analysis of the cleavage posi-
tions (Fig. 5) was performed by mass spectrometry,
which suggested that the three predominant fragments
were Ng38–78, Ng43–78 and Ng1–37. Several, mostly
N-terminal, shorter fragments were also detected in the
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digestion mix, indicating that the N-terminal half of Ng
is readily cleaved by calpain-1, whereas the C-terminal
half is more resistant to cleavage. These in vitro cleavage
data may explain the occurrence of some, but not all, of
the identified endogenous Ng peptides in CSF (Fig. 5).
The identified peptides of Ng in CSF have N-terminal
endings at aa 33, 41, 43, 44, 45, 46, 48 and 49 and most
of them (eight out of fifteen peptides identified) end at
aa 75 [6]. Thus, it appears that most of these fragments
may have originated from cleavage at or around
Ng42_43 and additional cleavage at Ng75_76.
Identification of prolyl endopeptidase as the enzyme
cleaving Ng near the C-terminus (aa 75_76)
As mentioned above, many of the endogenous Ng
CSF peptides end C-terminally at aa 75. Calpain-1 did
not cleave the quenched FRET probe Ng70–78 (Fig.
2). Thus, additional enzyme(s) may be responsible for
the cleavage at position 75. Such C-terminally cleaved
Ng peptides have been identified also in human brain
tissue using MALDI TOF/TOF [6], indicating that
brain tissue may be a good source for identifying the
C-terminally cleaving enzyme.
To increase the chance of detecting a
C-terminal-cleaving activity on Ng in such a complex
matrix, mouse brain extract was initially size-separated,
and the fractions were further analyzed for C-terminal
peptide cleaving activity (quenched FRET peptide repre-
senting Ng70–78). While the SEC column had the disad-
vantage of diluting the proteins during size separation, it
was still preferred to an ion-exchange column for this
initial experiment because of lower risk of losing activity
on the column by strong adsorption. Active fractions
were detected in the size range of about 44–73 kDa
(Fig. 6).
For a more detailed characterization of the active enzyme,
a larger scale purification was required but the capacity of
the size exclusion column was not sufficient. Therefore, a
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Fig. 1 Representative hybrid immunoaffinity (HI)-MS spectrum of Ng CSF peptides identified in CSF
Fig. 2 Calpain-1 cleaves the two quenched Ng peptides Ng39–51 and Ng31–40 (central region) but not the quenched peptide Ng70–78 (C-terminal
region). Ng39–51 Ctrl, Ng31–40 Ctrl, Ng70–78 Ctrl, quenched peptide in assay buffer without calpain I
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strategy involving an initial separation of mouse brain ex-
tract on an anion-exchange column, followed by ultrafiltra-
tion and buffer exchange to low salt buffer by SEC was
chosen (see Fig. 7). Anion-exchange chromatography
was then repeated on a high resolution anion--
exchange resin. For the final identification of the
C-terminal cleaving enzyme, fractions with high en-
zymatic activity from the anion-exchange column
were further separated in a native polyacrylamide gel
and bands containing enriched enzymatic activities lo-
calized by soaking the gel in the fluorogenic FRET
Ng70–78 peptide and imaging of the gel in UV-light
(Fig. 8). Fluorescent bands were cut out, reduced,
alkylated, trypsinated and prepared for LC-MS/MS
analysis. Using this strategy, sixty-two unique peptides of
prolyl endopeptidase (Q9QUR6; PPCE mouse) with a se-
quence coverage of > 85% were identified (see Add-
itional files 1 and 2). To confirm that active fractions
indeed were able to cleave off the three last amino acids at
the C-terminus of Ng (cleavage between Ng75 and Ng76),
synthetic peptide KKK-Ng50–78 (human aa sequence)
was incubated with the active fractions from the initial
anion-exchange column (Q-Sepharose) and the resulting
mix fractionated on a C18 reversed phase HPLC column.
Figure 9 shows a MALDI -TOF spectrum of one of the
fractions obtained. In the spectrum, a strong peak appears
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Fig. 4 Detection of C-terminal and N-terminal fragments of Ng in digests by calpain. Digestion products were analyzed in reducing SDS PAGE gels
(12%). Panel a Coomassie stain followed by silver stain; Panel b NG36 immunoblot; Panel c, H-6 immunoblot. Lanes 1, Ng control; lanes 2, 3 and 4, Ng
digest with 90-, 30-, 10-fold diluted calpain-1, respectively. The location of the parent Ng1–78 band is indicated on the right near panel c with an
arrow, those of the major ~ 5 kDa C-terminal fragments by an * in panel b, and those of the main N-terminal fragment near 6.5 kDa by a # in panel c.
Size markers for panel a as indicated
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at 2570.3 Da, which is 259 Da less than the substrate
KKK-Ng50–78 (2829.5 Da), thus indicating the presence
of specific 75_76 cleaving activity. In addition, cross spe-
cies activity to human PREP was confirmed by using
either recombinant mouse or human PREP in a cleavage
experiment on the human KKK-Ng50–78 peptide. Fur-
thermore, an identical HPLC retention time of a newly
formed elution peak with synthetic peptide KKK-Ng50–75
was observed for digestions of KKK-Ng50-78 with either
mouse or human PREP enzyme. To extend the results to
cleavage of larger Ng peptides, both either full length re-
combinant human Ng1–78 or a synthetic peptide of hu-
man Ng43–78 were digested in vitro with human PREP
enzyme. Cleavage products Ng1–75 and Ng43–75, re-
spectively, were identified by LC-MS/MS as minor
Fig. 5 Alignment of identified endogenous Ng peptides in CSF with the full-length Ng amino acid sequence above. The identities of the peptides are
given on the left, with the aa positions (N- and C-terminal) as indicated. Further, the line below the Ng sequence indicates the IQ domain with Ng’s
conserved amino acid positions for the IQ motif above the line. The arrows indicate the calpain-1 cleavage sites between Ng37_38 and Ng42_43
which are generating the three most abundant fragments (Ng38–78, Ng43–78 and Ng1–37). Note that these cleavage sites are within the IQ domain
Fig. 6 Activity profile of SEC column fractions (Superdex 200 size
exclusion column). Active fractions in the Ng C-terminal cleaving assay
are indicated by the two dashed vertical lines and corresponded to a
protein size range of approximately 44–73 kDa
Mouse brain extract
Anion-exchange chromatography
(Q-Sepharose)
Ultrafiltration (YM-10)
SEC (Superdex 200)
Anion-exchange chromatography
(Mono Q)
Ultrafiltration (10k spin-filter)
Native gel electrophoresis (10% Tris-Glycine PAGE)
Detection of active band by soaking of gel with fluorogenic peptide
Trypsin-digest of proteins in cut out band, reduction, alkylation
LC-ESI-MS/MS and database search using Mascot
Fig. 7 Strategy for enrichment of protease activity cleaving near the C-
terminal end of Ng and identification of enzyme by mass spectrometry
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products (approximately 1% MS signal area relative to
remaining uncleaved Ng peptide).
Discussion
Synaptic dysfunction and degeneration, which is key in
AD pathophysiology [1, 22–24], will lead to secretion
and/or release of synaptic proteins and their eventual in-
crease in the CSF of AD patients. Indeed, increased Ng
concentrations, as detected with sandwich ELISA and
mass spectrometry, have shown to detect AD already at
the mild cognitive impairment stage (MCI) of the dis-
ease [6] and may therefore be a useful clinical bio-
marker. Both full-length Ng and fragments of Ng have
been detected in CSF by western blotting and mass
spectrometry, respectively [5, 6]. The identified endogen-
ous Ng peptides originated from the C-terminal half of
the molecule [6].
This study focused on the proteolytic cleavage of Ng
with the aim to identify the enzymes involved in its
cleavages. Such cleavage may reduce the intracellular
level of Ng, or change its location, and consequently
attenuate the synaptic efficacy resulting in cognitive defi-
cits. Ng knock out mice have difficulties with spatial
memory and altered long-term potentiation (LTP) and
long-term depression (LTD) [19]. On the other hand, in-
creased levels of Ng have been reported to counteract
the effects of Aβ on synaptic transmission and LTP [20].
It is most often unknown what physiological factor trig-
gers the activation of proteases in the CNS that lead to
the degradation of cellular components and neurodegen-
erative diseases. Information on the enzymatic cleavage
35 38 35 38fr. #
Fig. 8 In situ localization of enzymatic activity in native PAGE
separated proteins. Two fractions (fr. #35 and #38 with either no
activity or with activity) were separated on a 10% Tris-glycine
gel. The location of enzymatic activity was revealed thereafter by
soaking the gel in fluorogenic quenched FRET peptide Ng70–78
(5-FAM_Ng70–78_QXL520). Note that only fraction #38 showed a
band of fluorescence but not the nearby inactive fraction #35).
The Coomassie-stained corresponding gel showed presence of
proteins in both fractions. Arrow, location of enzymatic activity
KKK-Ng50-75
(2570.3 Da)
KKK-Ng50-78
(2829.3 Da)
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Fig. 9 Active fractions during enzyme enrichment show cleaving activity at Ng75_76 (MALDI-TOF analysis). Synthetic KKK-Ng50–78 was incubated
with an active fraction and the reaction mix separated by HPLC. MALDI-TOF analysis of one of the HPLC fractions showed the presence of an [M+H]+
peak at 2570.3 Da which is consistent with a cleavage at Ng75_76 which releases –SGD (mass difference of 259 Da relative to the substrate KKK-Ng50–78)
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of synaptic proteins such as Ng may shed some light not
only into particular steps of the pathogenesis of AD, but
also into physiologic functions such as LTP and LTD
and offer options for pharmacological intervention. It
may also lead to identification of specific fragments of
Ng that reflect particular disease stages of AD and it
may point to potentially different mechanisms of synap-
tic dysfunction suggested by the biomarker studies of Ng
comparing various neurodegenerative diseases [8].
When comparing the sequences of 15 endogenous Ng
peptides found in CSF [6], it became apparent that the se-
quence of most of the peptides started around aa 41–49,
just at the C-terminal end of the IQ domain (aa 33–46) of
Ng [25], and most of them lacked the very last three
C-terminal amino acids (aa 76–78). Therefore, fluorogenic
quenched FRET probes containing sequences of Ng of
these cleavage regions were constructed. Three quenched
probes were constructed, one containing Ng39–51 and
another one containing Ng31–40, both for detecting the
central Ng cleavage, and one with Ng70–78 for detecting
C-terminal cleavage. Initially, the Ng39–51 central probe
was used to screen various candidate enzymes reported to
be activated during AD (such as BACE1, TACE-1, IDE,
and calpain-1). Of those, cleaving activity was found with
calpain-1 and this was confirmed by cleavage of recom-
binant Ng-Myc-DDK fusion protein, synthetic Ng1–78,
and recombinant Ng (all with human sequence).
Increased activation of calpain-1 has been reported in
brain samples of AD patients [26, 27] and several neur-
onal proteins are known substrates for calpain, e.g. αII
and βII spectrin, PSD95, MAP-2, GAP-43, calcineurin,
PKC, CaMKII, and NMDA receptors. While physio-
logical activation may have roles in rearranging cytoskel-
etal proteins or during remodeling of spine structures as
seen in LTP, pathological activation may lead to deple-
tion of essential components of neuronal signaling. It is
quite striking that the calpain-1 cleavage sites in Ng are
either in or adjacent to the IQ domain. Calpain-1 activity
thus generates fragments of Ng without an intact IQ do-
main, which thereby very likely lose their ability to bind
to CaM. This in turn may lead to defective Ca2+/CaM--
dependent protein kinase signaling with downstream
effects on LTP (as seen in Ng knockout mice). The
appearance of Ng fragments in CSF may therefore reflect
such changes occurring in the brain. The sequence of
Ng also contains a short sequence of basic amino acids
(Ng43–47; RKKIK) which may act as a nuclear trans-
location sequence and could be responsible for binding
activity to phosphatidic acid [28]. Upon cleavage of Ng
by calpain-1 between amino acids 42_43, fragments be-
ginning with this basic RKKIK sequence are formed and
potentially exposed – which in contrast to the uncleaved
Ng may have this RKKIK sequence covered by bound
CaM or PA. This may lead to translocation events for
the Ng fragments with consequences for cellular or
nuclear signaling. Nevertheless, this hypothesis needs to
be experimentally verified.
To embark on an unbiased screen to find enzymes
responsible for the C-terminal cleavage of Ng, we
probed mouse brain extract at various stages of chroma-
tographic fractionation with the C-terminal fluorogenic
quenched FRET probe Ng70–78. The anion exchange
column fraction that was most enriched in enzymatic
activity was further concentrated by ultrafiltration and
finally separated by native PAGE. The fluorogenic FRET
probe Ng70–78, soaked into the gel after the separation
of the active fraction, revealed the localization of the
enzymatic activity. The strongly fluorescing band was
cut out and used for LC-ESI-MS/MS identification of
the enzyme. Database searches identified mouse PREP
(Uniprot ID Q9QUR6; EC:3.4.21.26) as the main hit,
with 85% sequence coverage of the full-length protein by
tryptic peptides. PREP belongs to the family of serine
proteases, has a molecular weight of about 80 kDa and
cleaves peptides C-terminally after proline [29]. Indeed,
recombinant human and mouse PREP generated in vitro
the C-terminally truncated fragment KKK-Ng50–75
from synthetic KKK-Ng50–78 substrate, however, other
fragments derived by cleavage on other internal PREP
cleavage sites on the substrate predominated.
PREP is a cytosolic neuronal protein that binds to
microtubules and is also found in close association with
cell membranes [30], bringing it potentially into vicinity
of PA-bound Ng or other endogenous substrates. Add-
itionally, PREP enzyme activity has been detected in
CSF [31] using a sensitive HPLC method with fluori-
metric detection. Inhibition of the PREP enzyme has
been studied with regards to changes in Ins(1,4,5)P3
concentrations [32], improvements in memory function
in rats and monkeys, and a phase I study has been re-
ported in humans [33] . The known substrates of PREP
are small neuropeptides peptides, < 30 amino acids (aa)
long, such as substance P, thymosin β4. Longer peptides
may potentially enter the active site of the enzyme, but
only if they are of randomly disordered structure [34].
This raises the question whether full-length Ng can be
a substrate because it is substantially larger (78 aa).
Recombinant Ng1–78 and the calpain fragment of Ng,
Ng43–78, generated only small amounts of Ng1–75
and Ng43–75, respectively, when incubated with fairly
high concentrations of human PREP in vitro. Whether
this low ability of PREP enzyme to cleave longer Ng
peptides at Ng75_76 reflects a limitation of the in vitro
assay or non-ideal properties the synthetic peptide used
(e.g., due to cis/trans isomerism at proline positions, or
lack of posttranslational modifications), or whether it is
indeed due to a substrate size limitation of this enzyme,
is currently not known. Activity of PREP requires
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conformational changes, and therefore interaction of a
PREP enzyme-substrate complex with another cellular
protein to form an enzymatically active tertiary com-
plex may be needed [35]. A proteomic study in frac-
tionated brain extracts revealed increased levels of
α-synuclein and Ng peptides after in vitro incubation of
brain extracts with added PREP enzyme [36]. Interest-
ingly, the identified Ng48–56 peptide, SGERGRKGP,
starts at the same N-terminal position (Ng48) as two of
the endogenous Ng CSF peptides. Furthermore, another
proteomic study using the PREP inhibitor S17092 in
hypothalamus tissue extracts from mice, showed higher
levels of Ng54–75 in vehicle treated animals vs. those
treated with S17092 inhibitor [37]. The sequence of Ng
also contains a number of other prolines after which
PREP may also cleave. However, the cleavage sites were
not mapped in detail, as it may depend on the substrate
length and digestion conditions and it is difficult to
know which applies to the intracellular conditions.
For the generation of Ng peptides, we currently favor
a model which requires initial cleavage of Ng by en-
zymes active in neurons, such as calpain 1. This then de-
livers the shorter fragments for further cleavage by PREP
and possibly, additional proteases, and eventually gener-
ating the fragments of Ng that can be detected in CSF.
Consequently, patients enrolled in clinical trials for cal-
pain- and/or PREP inhibitors may show decreased con-
centrations of Ng fragments in CSF. Future work will be
needed to clarify the compartments in which Ng cleav-
ages occur (intra-neuronal, in the interstitial fluid, or in
CSF), the extent to which such cleavage occurs (frag-
ment amounts relative to full-length Ng) and its timing
in relation to AD pathology. This may give insights
about the role of Ng cleavage for the Ng reduction seen
in AD brain, and provide additional enzyme-specific
fragments of Ng as potential biomarkers for specific
stages of AD.
Conclusions
Calpain-1- and prolyl endopeptidase were identified as
enzymes generating the pattern of C-terminal fragments
of Ng detectable in CSF. Calpain-1 cleaves Ng in the IQ
domain, while prolyl endopeptidase cleaves after pro-
lines, resulting in C-terminal Ng peptides ending at
Ng75 which are predominantly found in CSF.
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